Samsung Bioepis’ Etanercept Nod Prompts US Lawsuit
Executive Summary
The FDA has approved Samsung Bioepis’ Eticovo as the second biosimilar competitor to Amgen’s blockbuster rheumatoid arthritis biologic Enbrel. Amgen immediately sued for patent infringement.
You may also be interested in...
Samsung Bioepis Also Faces 2029 Wait For US Etanercept Biosimilar
Samsung Bioepis’ etanercept biosimilar, freely available in Europe, will not be sold in the US until patent expiry in 2029 following action by a US district court.
Eight More Years: US Supreme Court Sinks Sandoz’ Hopes On Enbrel
Sandoz’ arguments urging the US Supreme Court to review patent litigation around Amgen’s Enbrel have fallen on deaf ears, blocking a route to market for biosimilar etanercept until 2029 in the US.
Patience Needed On US Biosimilars, Says Samsung Bioepis’ Ko
In the first part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out his views on the US biosimilar market.